Epidemiologic Study Evaluating Infections in Elderly Patients

This study has been completed.
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
First received: May 7, 2009
Last updated: October 8, 2009
Last verified: October 2009
The purpose of this observational study is to assess the prevalence and demographic and clinical characteristics of infections in elderly people admitted to Internal Medicine wards in Spain, as well as the etiology and resistance pattern for the main causal agents, and outcome.

Condition Intervention
Other: Clinical record review

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Epidemiologic Study of Infections in Elderly Patients

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • Prevalence of each kind of infection will be measured from a descriptive point of view, using relative and absolute frequencies. [ Time Frame: 5 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Study the etiology and resistance pattern for the main causal agents. [ Time Frame: 5 months ] [ Designated as safety issue: No ]
  • Describe the demographic features, co-morbidities, concomitant treatment and outcome of patients. [ Time Frame: 5 months ] [ Designated as safety issue: No ]

Enrollment: 240
Study Start Date: March 2009
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Infected elderly patients
Other: Clinical record review


Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Infected elderly patients treated at Internal Medicine wards in Spanish hospitals

Inclusion criteria:

  • Patients > 65 years of age that are hospitalized in an Internal Medicine ward and have an active infection (skin and soft tissue, intra-abdominal, or respiratory infections) from the community that needs antibiotic treatment
  • Patients must have at least one sample processed for microbiological diagnosis

Exclusion criteria:

  • COPD exacerbation
  • Urinary tract infections
  • Hospital acquired infections
  • Other infections not in inclusion criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00900952

Mataró, Barcelona, Spain, 08304
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
  More Information

Responsible Party: Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
ClinicalTrials.gov Identifier: NCT00900952     History of Changes
Other Study ID Numbers: 3074X1-4489 
Study First Received: May 7, 2009
Last Updated: October 8, 2009
Health Authority: Spain: Comité Ético de Investigación Clínica

Additional relevant MeSH terms:

ClinicalTrials.gov processed this record on April 27, 2016